ARK Genomic Revolution ETF rebounds after 15% drop, showing strong technical support and growth potential.

The ARK Genomic Revolution ETF (ARKG) is considered a buy following a 15% correction from its July highs, with its valuation improving and technical support emerging around $34–$35. The ETF's portfolio is focused on small- and mid-cap biotech companies, with its top 10 holdings making up 59% of assets and a long-term EPS growth rate of 10.7%. Despite challenges like weak seasonality and high volatility, ARKG benefits from a rising 200-day moving average and favorable market conditions driven by regulatory reforms, risk-on sentiment, and stable or falling interest rates. This makes ARKG attractive for investors who can tolerate volatility and seek growth in the biotech sector.